Enhanced Verifiable CPD from the
University of Birmingham

Dentaljuce Shorts: 500 words, 10 MCQs, on general medicine and surgery.

Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) or Lou Gehrig's Disease in the United States, is a rare neurodegenerative disorder that results in the progressive loss of upper and lower motor neurons, leading to muscle weakness and atrophy. The disease was first described by French neurologist Jean-Martin Charcot in 1869.

Diagram of a human nervous system highlighting the brain, spinal cord, motor neurons, and muscles of the body affected by ALS
Parts of the nervous system affected by ALS, causing progressive symptoms in skeletal muscles throughout the body

Signs & Symptoms

Early symptoms of ALS include muscle stiffness, twitching, and gradual weakness. As the disease progresses, individuals experience difficulty speaking, swallowing, and breathing. Over time, ALS leads to total paralysis and respiratory failure. Approximately 10-15% of patients develop frontotemporal dementia, and many others experience minor cognitive and behavioural difficulties.

Illustration showing the range of upper and lower motor neuron involvement in ALS
Classic ALS involves neurons in the brain and spinal cord (upper motor neurons, highlighted red), as well as the lower motor neurons, which go from the spinal cord to the muscles, highlighted teal.


Diagnosing ALS involves a clinical diagnosis of exclusion based on progressive symptoms of upper and lower motor neuron degeneration. Supportive evidence is obtained from electromyography, genetic testing, and neuroimaging. Differential diagnoses include multifocal motor neuropathy, Kennedy's disease, hereditary spastic paraplegia, nerve compression syndrome, diabetic neuropathy, post-polio syndrome, myasthenia gravis, and multiple sclerosis.

MRI of the brain showing increased T2 signal consistent with ALS
An MRI of the brain (axial FLAIR) showing increased T2 signal as a small white region within the posterior part of the internal capsule around the centre of the image, consistent with the diagnosis of ALS


There is no known cure for ALS, and treatment focuses on slowing disease progression and managing symptoms to improve quality of life. Medications such as riluzole and edaravone can modestly extend survival. Non-invasive ventilation improves both quality and length of life, while mechanical ventilation can prolong survival without halting disease progression. Feeding tubes may be necessary to maintain nutrition.

Person with ALS and their assistive technologies
A person with late-stage ALS with a range of assistive technologies to support movement (power wheelchair), breathing (invasive ventilation), and communication (eye tracker and computer)


Riluzole has been found to modestly prolong survival by about 2–3 months. Edaravone slows functional decline in early-stage ALS. Sodium phenylbutyrate/ursodoxicoltaurine extends life by around seven months. Tofersen, an antisense oligonucleotide, is used for SOD1-associated ALS.

Chemical structure of riluzole
Chemical structure of riluzole, a medication that prolongs survival by 2–3 months

Supportive Therapies

Physical therapy, occupational therapy, and speech therapy are very important in managing ALS. These therapies help maintain function, alleviate pain, and improve speech and swallowing. Assistive technologies like power wheelchairs, feeding tubes, and communication devices are often required as the disease progresses.

A man with ALS communicates with his wife by pointing to letters and words with a head-mounted laser pointer
A man with ALS communicates by pointing to letters and words using a head-mounted laser pointer

Prognosis and Epidemiology

The average survival from onset to death is two to four years, though about 10% of those affected survive longer than ten years. The incidence of ALS is approximately 1.6 per 100,000 individuals per year, and the lifetime risk is about 1 in 400 individuals. ALS is more common in men and typically presents between ages 45 and 75.

Estimated prevalence of ALS in the United States by age group, 2012–2015
Estimated prevalence of ALS in the United States by age group, 2012–2015


Descriptions of ALS date back to at least 1824. Jean-Martin Charcot first described the connection between symptoms and underlying neurological problems in 1869 and coined the term amyotrophic lateral sclerosis in 1874. ALS is sometimes referred to as Charcot's disease, and in the United States, it is often called Lou Gehrig's Disease after the famous baseball player.

Jean-Martin Charcot
The French neurologist Jean-Martin Charcot coined the term amyotrophic lateral sclerosis in 1874.
American baseball player Lou Gehrig
American baseball player Lou Gehrig. In some countries, especially the United States, ALS is called "Lou Gehrig's disease".

Self-assessment MCQs (single best answer)

What is another name for Amyotrophic Lateral Sclerosis (ALS) in the United States?

Which neurologist first described ALS and coined its name?

Which of the following is NOT a common early symptom of ALS?

What does the acronym ALS stand for?

Which of the following medications is known to modestly prolong survival in ALS patients?

Which diagnostic tool is NOT typically used to support the diagnosis of ALS?

Which part of the nervous system is primarily affected by ALS?

What percentage of ALS patients develop frontotemporal dementia?

What is the average survival time from onset to death for ALS patients?

Which therapy is NOT typically used as supportive care in ALS?


Dentaljuce provides Enhanced Continuing Professional Development (CPD) with GDC-approved Certificates for dental professionals worldwide.

Founded in 2009 by the award-winning Masters team from the School of Dentistry at the University of Birmingham, Dentaljuce has established itself as the leading platform for online CPD.

With over 100 high-quality online courses available for a single annual membership fee, Dentaljuce offers comprehensive e-learning designed for busy dental professionals.

The courses cover a complete range of topics, from clinical skills to patient communication, and are suitable for dentists, nurses, hygienists, therapists, students, and practice managers.

Dentaljuce features Dr. Aiden, a dentally trained AI-powered personal tutor available 24/7 to assist with queries and provide guidance through complex topics, enhancing the learning experience.

Check out our range of courses, or sign up now!

Membership Options

Dentaljuce offers a range of membership options…

Regular Membership

With enhanced CPD Certificates. Dentaljuce is brought to you by the award winning Masters team from the School of Dentistry, University of Birmingham, UK. All have won awards for web based learning and teaching and are recognised as leaders and innovators in this field, as well as being highly experienced clinical teachers. Full access to over 100 courses, no extras to pay.

Buy Now

£89.00 per year

Student Membership

No Certificates. With universities cutting down on traditional lectures, many students are currently having to rely more on online resources. If you don't need CPD Certificates, we are offering an amazing discount on your Dentaljuce personal membership fee. Special student price just £29 for 12 months individual membership.

Buy Now

£29.00 per year

Very good, detail excellent, very clear to use.

© Dentaljuce 2024 | Terms & Conditions | Privacy Policy

Recording CPD time: recorded.